Trial reportGut and liver2022
Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of
Trial report in Gut and liver, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 56 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Efficacy of Bismuth-containing Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection in 10 Days and 14 Days: a Prospective, Randomized, Controlled Study
Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Amoxicillin 1g + Clarithromycin 500 mg and Tegoprazan 50 mg vs Amoxicillin 1g + Clarithromycin 500 mg and Esomeprazole 40 mg Twice a Day for 14 Days
Who cites it
56 citing papers in PubMed, 8 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- Efficacy of Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors in Eradication Regimens for Clarithromycin-ResistantPathogens (Basel, Switzerland) · 2026Pooled it
- [Evidence-Based Guidelines for the Diagnosis and Treatment ofThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2026Guideline
- Comparing potassium-competitive acid blocker-based therapies forFrontiers in physiology · 2026Pooled it
- Pooled it
- Comparison of tegoprazan-based and proton pump inhibitor-based regimens forFrontiers in medicine · 2025Pooled it
- Treatment ofWorld journal of gastroenterology · 2024Pooled it
- Tegoprazan as First- and Second-Line Therapy for Eradication of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis.Journal of digestive diseasesPooled it
- Guideline
- Trial
- Comparative Efficacy of Potassium-Competitive Acid Blocker-Based Triple Therapy with Tegoprazan versus Vonoprazan forGut and liver · 2025Trial
- The Effect of Tegoprazan on the Treatment of Endoscopic Resection-Induced Artificial Ulcers: A Multicenter, Randomized, Active-Controlled Study.Gut and liver · 2024Trial
- Evolving landscape of potassium-competitive acid blockers: toward disease-specific use beyond acid suppression.Journal of gastroenterology · 2026Review
- Potassium-Competitive Acid Blockers as a New Frontier in Acid-Related Disorders and the Role of South Korean Pharmacological Innovation.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Evidence-Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised Edition.The Korean journal of helicobacter and upper gastrointestinal research · 2026Review
- Tegoprazan in Gastroesophageal Reflux Disease and Related Acid-Mediated Conditions: A Systematic Review and Meta-Analysis.JGH open : an open access journal of gastroenterology and hepatology · 2026Review
- Treatment of Helicobacter pylori Infection in Korea: An Evidence-Based Analysis of the Upcoming 2025 Guideline.The Korean journal of helicobacter and upper gastrointestinal research · 2026Review
- OptimizingWorld journal of gastroenterology · 2026Article
- Establishing Epidemiological Cutoff Values forGut and liver · 2026Article
- Efficacy and safety of potassium-competitive acid blockers in eradicatingCaspian journal of internal medicine · 2026Review
- Research progress of potassium-competitive acid blockers in the treatment ofAnnals of medicine · 2025Review
Corrections and comments
- Commented on by
Authors and funding
21 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: We examined the efficacy and safety of tegoprazan as a part of first-line triple therapy for Methods: A randomized, double-blind, controlled, multicenter study was performed to evaluate whether tegoprazan (50 mg)-based triple therapy (TPZ) was noninferior to lansoprazole (30 mg)- based triple therapy (LPZ) (with amoxicillin 1 g and clarithromycin 500 mg; all administered twice daily for 7 days) for treating Results: In total, 350 Conclusions: TPZ is as effective as proton pump inhibitor-based triple therapy and is as safe as first-line
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.